EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss of $0.62, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
EyePoint Pharmaceuticals (EYPT) Reports Election of Goran Ando M.D. as Next Board Chairman
September 10, 2018 7:03 AM EDTEyePoint Pharmaceuticals (NASDAQ: EYPT) today announced that the Companys Board of Directors has elected Göran Ando, M.D., as its next Chairman of the Board. As part of this transition, David J. Mazzo, Ph.D., will step-down as Non-Executive Chairman, but will remain on the Board and will continue to serve as Chair of the Compensation Committee.
We are pleased to have Dr. Ando serve as our Chairman of the Board as we continue our transition into a commercial-stage specialty pharmaceuticals company, said Nancy... More
